84 related articles for article (PubMed ID: 34962357)
1. Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases.
Bitoun S; Henry J; Desjardins D; Vauloup-Fellous C; Dib N; Belkhir R; Mouna L; Joly C; Bitu M; Ly B; Pascaud J; Seror R; Roque Afonso AM; Le Grand R; Mariette X
Arthritis Rheumatol; 2022 Jun; 74(6):927-933. PubMed ID: 34962357
[TBL] [Abstract][Full Text] [Related]
2. Impact of rituximab on humoral response to SARS-CoV-2 vaccination in previously vaccinated patients with autoimmune diseases.
Oliosi E; Flahault A; Charre C; Veyer D; Combier A; Lafont E; Karras A; Mouthon L; Avouac J; Terrier B; Hadjadj J
Clin Rheumatol; 2023 Sep; 42(9):2485-2490. PubMed ID: 37243801
[TBL] [Abstract][Full Text] [Related]
3. Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab.
Tolf A; Wiberg A; Müller M; Nazir FH; Pavlovic I; Laurén I; Mangsbo S; Burman J
JAMA Netw Open; 2022 May; 5(5):e2211497. PubMed ID: 35544139
[TBL] [Abstract][Full Text] [Related]
4. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.
Jyssum I; Kared H; Tran TT; Tveter AT; Provan SA; Sexton J; Jørgensen KK; Jahnsen J; Kro GB; Warren DJ; Vaage EB; Kvien TK; Nissen-Meyer LH; Anderson AM; Grødeland G; Haavardsholm EA; Vaage JT; Mjaaland S; Syversen SW; Lund-Johansen F; Munthe LA; Goll GL
Lancet Rheumatol; 2022 Mar; 4(3):e177-e187. PubMed ID: 34977602
[TBL] [Abstract][Full Text] [Related]
5. Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis.
Holm-Yildiz S; Dysgaard T; Krag T; Pedersen BS; Hamm SR; Pérez-Alós L; Hansen CB; Pries-Heje MM; Heftdal LD; Hasselbalch RB; Fogh K; Madsen JR; Frikke-Schmidt R; Hilsted LM; Sørensen E; Ostrowski SR; Bundgaard H; Garred P; Iversen K; Nielsen SD; Vissing J
J Neuroimmunol; 2023 Nov; 384():578215. PubMed ID: 37797472
[TBL] [Abstract][Full Text] [Related]
6. B Cell Reconstitution is Associated With COVID-19 Booster Vaccine Responsiveness in Patients Previously Seronegative Treated With Rituximab.
Schultz K; Jannat-Khah D; Spiera R
J Rheumatol; 2023 Mar; 50(3):420-425. PubMed ID: 36521910
[TBL] [Abstract][Full Text] [Related]
7. Analysis of factors involved in the development of humoral response to vaccination against SARS-CoV-2 in patients with rheumatic pathology under biological treatment.
Flores-Fernández E; Vázquez-Gomez I; Valls-Pascual E; Valera-Ribera C; Andújar-Brazal P; Alegre-Sancho JJ
Reumatol Clin (Engl Ed); 2023 Dec; 19(10):565-570. PubMed ID: 38008603
[TBL] [Abstract][Full Text] [Related]
8. Higher and Sustained Cell-Mediated Immune Responses After 3 Doses of mRNA COVID-19 Vaccine in Patients With Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy.
Caldera F; Rolak S; Farraye FA; Necela BM; Cogen D; Zona EE; Schell TL; Ramirez OR; Almasry M; Chun K; Hayney MS; Knutson KL
Clin Transl Gastroenterol; 2024 Apr; 15(4):e00688. PubMed ID: 38349178
[TBL] [Abstract][Full Text] [Related]
9. Expansion of cytotoxic tissue-resident CD8
Ssemaganda A; Nguyen HM; Nuhu F; Jahan N; Card CM; Kiazyk S; Severini G; Keynan Y; Su RC; Ji H; Abrenica B; McLaren PJ; Ball TB; Bullard J; Van Caeseele P; Stein D; McKinnon LR
Nat Commun; 2022 Jun; 13(1):3357. PubMed ID: 35688805
[TBL] [Abstract][Full Text] [Related]
10. B and T cell responses to the BNT162b2 COVID-19 mRNA vaccine are not impaired in germ-free or antibiotic-treated mice.
Norton T; Lynn MA; Rossouw C; Abayasingam A; Perkins G; Hissaria P; Bull RA; Lynn DJ
Gut; 2024 Jun; 73(7):1222-1224. PubMed ID: 37500502
[No Abstract] [Full Text] [Related]
11. SARS-CoV-2 infection risk is higher in vaccinated patients with inflammatory autoimmune diseases or liver transplantation treated with mycophenolate due to an impaired antiviral immune response: results of the extended follow up of the RIVALSA prospective cohort.
Rizzi M; Tonello S; Brinno C; Zecca E; Matino E; Cittone M; Rizzi E; Casciaro GF; D'Onghia D; Colangelo D; Minisini R; Bellan M; Castello LM; Chiocchetti A; Pirisi M; Rigamonti C; Lilleri D; Zavaglio F; Bergami F; Sola D; Sainaghi PP
Front Immunol; 2023; 14():1185278. PubMed ID: 37545528
[TBL] [Abstract][Full Text] [Related]
12. Immune response after SARS-CoV-2 vaccination in patients with inflammatory immune-mediated diseases receiving immunosuppressive treatment.
Plasencia-Rodríguez C; Martínez-Feito A; Hernández M; Del Pino-Molina L; Novella-Navarro M; Serrano Y; González-Muñoz M; Peiteado D; Bonilla G; Monjo I; Nuño L; Tornero C; López-Granados E; Balsa A; Nozal P
Allergy Asthma Clin Immunol; 2023 Aug; 19(1):71. PubMed ID: 37598192
[TBL] [Abstract][Full Text] [Related]
13. Determination of the factors associated with antigen-specific CD4+ T-cell responses to BNT162b2 in patients with rheumatoid arthritis.
Sagawa F; Yamada H; Ayano M; Kimoto Y; Mitoma H; Ono N; Arinobu Y; Kondo M; Nakashima Y; Akashi K; Horiuchi T; Niiro H
RMD Open; 2024 Jan; 10(1):. PubMed ID: 38216287
[TBL] [Abstract][Full Text] [Related]
14. Early immunologic response to mRNA COVID-19 vaccine in patients receiving biologics and/or immunomodulators.
Rodríguez-Martinó E; Medina-Prieto R; Santana-Bagur J; Santé M; Pantoja P; Espino AM; Sariol CA; Torres EA
medRxiv; 2021 Sep; ():. PubMed ID: 34545370
[TBL] [Abstract][Full Text] [Related]
15. Optimisation of SARS-CoV-2 peptide stimulation and measurement of cytokine output by intracellular flow cytometry and bio-plex analysis.
Taylor JV; Callery EL; Rowbottom A
J Immunol Methods; 2023 Nov; 522():113556. PubMed ID: 37683822
[TBL] [Abstract][Full Text] [Related]
16. Use of Immunosuppressants/Immunomodulators in Autoimmune/Inflammatory Dermatologic Diseases during COVID-19 Pandemic-General Recommendation Based on Available Evidence.
De D; Pandhi D
Indian Dermatol Online J; 2020; 11(4):526-533. PubMed ID: 32832437
[No Abstract] [Full Text] [Related]
17. COVID-19 vaccine failure in a patient on rituximab therapy.
Chilimuri S; Mantri N; Zahid M; Sun H
Rheumatol Adv Pract; 2021; 5(2):rkab038. PubMed ID: 34159292
[No Abstract] [Full Text] [Related]
18. COVID-19 vaccine triggers autoimmune disease? Possible mechanism and current evidence.
Yeh LY; Chang CY; Chang R; Wei JC
Int J Rheum Dis; 2024 Jan; 27(1):e14963. PubMed ID: 37971170
[No Abstract] [Full Text] [Related]
19. Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability.
Carlson AK; Amin M; Cohen JA
Drugs; 2024 Mar; 84(3):285-304. PubMed ID: 38480630
[TBL] [Abstract][Full Text] [Related]
20. Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD20 therapy.
Priddey A; Chen-Xu MXH; Cooper DJ; MacMillan S; Meisl G; Xu CK; Hosmillo M; Goodfellow IG; Kollyfas R; Doffinger R; Bradley JR; Mohorianu II; Jones R; Knowles TPJ; Smith R; Kosmoliaptsis V
Front Immunol; 2023; 14():1296148. PubMed ID: 38259440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
